China’s Jiangsu Bioda Gains NMPA Approval for Innovative Artificial Blood Vessel
The National Medical Products Administration (NMPA) has granted marketing approval to China-based Jiangsu Bioda Life...
Visen Pharmaceuticals Publishes Phase III Data for Lonapegsomatropin in Growth Hormone Deficiency
Visen Pharmaceuticals, a China-based joint venture between Denmark-headquartered Ascendis Pharma and Chinese healthcare-focused investment firm...
RongCan Biotech Raises Pre-Series A Funding for mRNA Therapeutics Development
China-based nucleic acid-based therapeutics developer RongCan (Shanghai) Biotech Co., Ltd has reportedly raised “tens of...
Lee’s Pharmaceutical Reports Q3 2022 Financials with 8.8% Revenue Growth
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its Q3 2022 financial report, recording...
Marinus Pharmaceuticals Collaborates with Tenacia Biotechnology for Ganaxolone
Pennsylvania-based pharma company Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) has entered into a collaboration and supply...
Mirati Therapeutics Sues InventisBio Over Trade Secret Misappropriation
US-based Mirati Therapeutics (Nasdaq: MRTX) is reportedly suing China-based InventisBio Co., Ltd (SHA: 688382) over...
CDE Issues Trial Rules for NMPA Drug Review Timekeeping Suspension
The Center for Drug Evaluation (CDE) has released the “NMPA Drug Review Timekeeping Suspension and...
Bio-Heart Bio to Launch Clinical Study for Rapamycin Drug-Eluting Balloon in Japan
China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced that it will initiate...
Bio-Heart Bio Receives Ethical Approval for Iberis RDN System in Hainan
China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced receiving ethical approval from...
BeiGene’s Brukinsa Receives EC Approval for CLL Treatment
China-based biotech BeiGene Ltd. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced receiving marketing approval...
Zhangjiang AI New Drug R&D Alliance Expands with New Members
The Zhangjiang AI New Drug R&D Alliance has welcomed new participants, including Regor Therapeutics, Roche,...
Subtle Medical Secures Series B Funding for AI-Powered Medical Imaging
Subtle Medical, an Artificial Intelligence (AI)-empowered medical imaging company based in Guangdong, has reportedly raised...
Hengrui Pharmaceuticals Receives Clinical Trial Approvals for Three New Drugs
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving clinical trial approvals for three in-house...
Rainsure Scientific Secures Series C1 Funding for Digital PCR Development
Rainsure Scientific, a Suzhou-based developer of digital PCR instruments and RUO detection kits, has reportedly...
CSPC Pharma’s rhTNK-tPA Accepted for Review by NMPA for Stroke Indication
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that a supplementary market filing for...
Asia Pacific Medical Group Secures Series A Funding for Hospital Expansion
Private healthcare group Asia Pacific Medical Group (APMG) has raised “hundreds of millions” of renminbi...
Haisco’s HSK31858 Gains Ethical Approval for Phase II Study in NCFBE
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its drug candidate HSK31858...
CANbridge’s CAN106 Receives Orphan Drug Designation for Myasthenia Gravis
China-based rare disease firm CANbridge Pharmaceuticals Inc. (HKG: 1228) has announced receiving Orphan Drug Designation...
HitGen Partners with Guangzhou AIChemEco for Automated Synthesis Technology
China-based HitGen Inc. (SHA: 688222) has announced a partnership with compatriot firm Guangzhou AIChemEco. The...
Harbour BioMed Establishes Nona Biosciences for Next-Generation Antibody Development
Harbour BioMed (HKG: 2142), a biotech company with operations in the Netherlands, the United States,...